Endovascular Repair of Abdominal Aorta, lower mortality rates than conventional open surgery in younger than 70.

Original title: Long Term Comparison of Endovascular and Repair of Abdominal Aortic Aneurysm (OVER TRIAL) Reference: Frank A. Lederle, et al. NEJM 367;24:1988-1997

Randomized studies had shown that the endovascular approach reduces mortality, yet its long term evolution remained a concern. 

The aim of this study was to analyze long term evolution of EVAR device implantation vs. conventional open surgery (OS) in treating Abdominal Aorta Aneurysm (AAA). This randomized trial included 881 patients (444 in the EVAR group and 437 in the OS group). 

Patients were eligible for the study if the aneurysm had a maximum external diameter of at least 50 mm. Primary end point was long-term mortality from any cause and secondary end point was quality of life and erectile dysfunction.

Baseline characteristics were similar for both populations. Long-term follow up (8 years) showed no difference in all-cause mortality rate in both groups (32.9% vs. 33.4% p=0.81), neither were differences in associated mortality rate (2.3% vs. 3.7% p=0.22). 

Secondary end point did not show significant differences. Long-term survival rate in patients younger than 70 was better in the EVAR group (hazard ratio 0.65; 95% CI, 0.43 to 0.98; p=0.04); this difference was not observed in patients older than 70 (hazard ratio,1.31;95% CI; 0.99 a 1.73; p=0.06).

Conclusion 

In this randomized study, infrarenal AAA repair showed similar results with both procedures in the long-term. Survival rate was better in patients

Editorial Comment:

In this multicenter randomized trial comparing AAA repair with EVAR vs. OS, there were no significant differences in long-term mortality rate, which are promising results considering aortic endoprosthesis implants reduce hospitalization time and facilitates recovery without altering quality of life, compared to the traditional open surgery. It is worth noting that the results for patients over 70, which were intuitively supposed to benefit more from this approach, were not the expected. However, further advances in new devices will bring the same, and even better, results in the treatment of more complex AAA. 

Courtesy of Carlos Fava, MD
Interventional cardiologist
Fundación Favaloro – Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...